Filing Flows › Bioventus (BVS) › Q3 2026
Bioventus (BVS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Bioventus (BVS) reported revenue of $142M for the third quarter 2026 (Q3 2026), +3% from a year earlier and -7% from the quarter before. Operating margin was 6.8%, net earnings $6.0M (4.2% of revenue).
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $142M | -7% | +3% |
| Gross profit | $97.1M | -8% | +3% |
| Operating profit | $9.7M | -49% | -14% |
| Net earnings | $6.0M | -82% | +90% |
| Operating cash flow | $20.7M | +4% | -31% |
| Free cash flow | $20.3M | +7% | -31% |
What changed
Revenue was $142.4M in Q3 2026, up 3% year over year and down 7% from the previous quarter.
Gross margin was 68.2%, up 0.2 points from Q3 2025. Operating profit was $9.7M, a 6.8% margin (down 1.3 points year over year). Operating profit fell $1.6M even though revenue rose $3.8M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 5% against revenue growth of 3%. The fastest-growing cost line was Research & development (+18%). Net earnings were $6.0M, up 90% year over year. The effective tax rate was -11.4%.
Operating cash flow was $20.7M (down 31% year over year), 301% of net income including minority interests. Non-cash charges added back $10.3M of depreciation and amortization and $4.8M of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $334K left free cash flow of $20.3M.
Questions
What was Bioventus' revenue in the third quarter 2026?
Bioventus (BVS) reported revenue of $142M for the third quarter 2026 (Q3 2026), +3% from a year earlier and -7% from the quarter before.
Was Bioventus profitable in the third quarter 2026?
Operating profit was $9.7M (6.8% of revenue) and net earnings $6.0M.
Source: Bioventus 10-Q on SEC EDGAR.